S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women



Status:Terminated
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 120
Updated:8/12/2018
Start Date:November 2004
End Date:July 2009

Use our guide to learn which trials are right for you!

Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of celecoxib may be effective in preventing
breast cancer.

PURPOSE: This randomized phase II trial is studying how well celecoxib works in preventing
breast cancer in premenopausal women who are at risk for developing the disease.

OBJECTIVES:

- Compare 1-year mammographic density in premenopausal women at high risk for developing
breast cancer treated with celecoxib vs placebo.

- Compare 1-year proliferation of breast epithelial cells, as measured by Ki67 staining,
in patients treated with these drugs.

- Compare the expression of other biomarkers, including cyclo-oxygenase-2 (COX-2) enzyme
and a marker of apoptosis, in breast tissue of patients treated with these drugs.

- Compare 1-year plasma levels of insulin-like growth factor (IGF)-1, IGF binding
protein-3, and prostaglandin E_2 in patients treated with these drugs.

- Compare the toxicity of these drugs in these patients.

OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients
are stratified according to risk category (lobular carcinoma in situ or ductal carcinoma in
situ vs BRCA1/2 mutation AND any Gail risk vs Gail risk ≥1.7% but < 5% vs Gail risk ≥ 5%) and
prior tamoxifen use (yes vs no). Patients are randomized to 1 of 2 treatment arms.

- Celocoxib: Patients receive oral celecoxib twice daily.

- Placebo: Patients receive oral placebo twice daily. In both arms, treatment continues
for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.

Patients are followed at 1 month.

PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this
study.

DISEASE CHARACTERISTICS:

- At elevated risk of developing breast cancer, as defined by 1 of the following:

- Modified Gail risk at 5 years ≥ 1.7% or lifetime risk ≥ 20% AND Claus Model,
BRCAPro Model, or Tyrer-Cuzick Model lifetime risk ≥ 20%

- Diagnosis of lobular carcinoma in situ or ductal carcinoma in situ

- Known deleterious mutation of BRCA1 or BRCA2

- At least 1 breast available for imagery and biopsy

- Has undergone a baseline mammogram with a standard density wedge within 7-14 days
after completion of the last menstrual period AND within 7 days before study entry

- Mammogram normal or benign (BIRADS score 0 or 1)

- Hormone receptor status:

- Not specified

PATIENT CHARACTERISTICS:

Age

- 18 and over

Sex

- Female

Menopausal status

- Premenopausal, defined by 1 of the following criteria:

- Last menstrual period < 6 months ago AND no prior bilateral ovariectomy AND not
on estrogen replacement therapy

- Prior hysterectomy (with ovaries still in place) AND normal follicle-stimulating
hormone levels within 28 days of study entry

Performance status

- Zubrod 0-1

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Bilirubin < 2.0 times institutional upper limit of normal (IULN)

- SGOT or SGPT < 2 times IULN

- Alkaline phosphatase < 2 times IULN

- INR ≤ 1.5

- PT and PTT ≤ IULN

Renal

- Serum creatinine < 2.0 times IULN

Cardiovascular

- No history of myocardial infarction

- No angina pectoris

- No known coronary artery disease

- No history of stroke or mini-stroke (e.g., transient ischemic attack)

- No history of thromboembolic disease (e.g., deep vein thrombosis or pulmonary
embolism)

- No uncontrolled hypertension (i.e., blood pressure > 140/90 mmHg)

Pulmonary

- No asthma after taking aspirin or other NSAIDs

Other

- No known sensitivity to celecoxib

- No allergy to sulfonamides

- No urticaria or allergic-type reactions after taking aspirin or other NSAIDs

- No extreme lactose intolerance

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer, carcinoma in situ of the cervix, or early bladder cancer
(preinvasive transitional cell carcinoma of the bladder)

- Not pregnant or nursing

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

- More than 5 years since prior biologic therapy for cancer

Chemotherapy

- More than 5 years since prior chemotherapy for cancer

Endocrine therapy

- At least 28 days since prior tamoxifen

- No prior systemic estrogen modifiers (SERMs) or aromatase inhibitors

- Concurrent hormonal contraception (i.e., pills, patches, or shots) allowed provided
contraception was initiated prior to study entry

Radiotherapy

- No prior radiotherapy to the breast to be studied

Surgery

- Not specified

Other

- At least 7 days since prior anticoagulant therapy

- More than 1 month since prior chronic daily aspirin or nonsteroidal anti-inflammatory
drugs (NSAIDs) of more than 7 days duration

- Concurrent intermittent aspirin or NSAIDs allowed (no more than 10 days per
month)

- No concurrent participation in another clinical trial for treatment or prevention of
cancer unless no longer receiving treatment and is in the follow-up phase
We found this trial at
9
sites
14
mi
from 91732
Glendale, CA
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
651
mi
from 91732
Albuquerque, NM
Click here to add this to my saved trials
747 Broadway
Seattle, Washington 98122
206-386-6000
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus Since 1910, Swedish has...
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-4100
University Cancer Center at University of Washington Medical Center The Division of Radiation Oncology's work...
943
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
One Baylor Plaza
Houston, Texas 77030
(713) 798-4951
Baylor University Medical Center - Houston Baylor University Medical Center in Dallas began in 1903...
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
1504 Taub Loop
Houston, Texas 77030
(713) 873-2000
Ben Taub General Hospital Located in the heart of the Texas Medical Center, Ben Taub...
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials